The goal of this woldwide observational study is to investigate various aspects of fluid and vasopressor therapy in critically ill invasively ventilated patients. The main questions it aims to answer are: * What is the global current practice of fluid and vasopressor therapy? * What are associations between this practice and clinical outcomes? Participating intensive care units will gather detailed information about fluid and vasopressor therapy prescribed to participants. Participating intensive care units will also gather information about participant outcomes such as duration of invasive ventilation, length of stay and mortality
Rationale: The worldwide practice of fluid and vasopressor therapy in critically ill invasively ventilated patients is uncertain. Indeed, it is unclear whether there is a difference in fluid and vasopressor therapy in these patients between Low- and Middle-income Countries (LMICs) and High-income Countries (HICs). Objective: To determine various aspects of fluid and vasopressor therapy in critically ill invasively ventilated patients in LMICs and HICs. Hypothesis: There is substantial worldwide variation in practice of fluid and vasopressor therapy in critically ill invasively ventilated patients. Study design: International, multicenter, observational study in critically ill invasively ventilated patients; data are captured during a predefined period per geographic region or country. Study population: Critically ill invasively ventilated patients. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Because of the observational design of the study using routinely collected data, there is no additional burden for the patient. Collection of data from ICU charts or electronic medical records systems is of no risk to the patients.
Study Type
OBSERVATIONAL
Enrollment
2,508
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Composite of various aspects of fluid therapy
Including total volumes of types of fluids administered in the first three days after ICU admission and total volume of fluids infused in the first seven days of ICU admission
Time frame: seven days
Timing of start of continuous administration of vasopressors.
Timing of start of vasopressors from ICU admission in minutes per administration route (i.e. central versus peripheral)
Time frame: seven days
Duration of vasopressor therapy
In days
Time frame: seven days
Types of vasopressors
The type (i.e. noradrenaline, vasopressin, adrenaline) of vasopressors that are prescribed
Time frame: seven days
Concentration of types of vasopressors
The concentration (i.e. in µg/ml) of vasopressors that are prescribed per administration route
Time frame: seven days
Timing of start of administered diuretics.
Time between start of invasive ventilation and administration of diuretics in days
Time frame: seven days
Duration of diuretic therapy
In days
Time frame: seven days
Types of diuretics
The type of diuretics that are prescribed
Time frame: seven days
Bolus or continous infusion of diuretics
Time frame: seven days
Cumulative fluid balances
Time frame: seven days
Daily urine output
Time frame: seven days
Incidence of atrial arrythmias
Time frame: 7 days
Incidence of acute respiratory distress syndrome
Time frame: 7 days
Incidence of renal replacement therapy
Time frame: 7 days
Incidence of need for renal replacement therapy at ICU discharge.
Time frame: 90 days
Typical ICU outcomes; e.g. duration of ventilation, lengths of stay in ICU and hospital and, mortality in the ICU and hospital
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.